Advanced search
Publication Cover
Journal of Pain Research Volume 13, 2020 - Issue
Submit an article Journal homepage
300
Views
6
CrossRef citations to date
0
Altmetric
Original Research

A Randomized, Open-Label, Bioequivalence Study of Lidocaine Topical System 1.8% and Lidocaine Patch 5% in Healthy Subjects

Jeffrey Gudin1 Department of Anesthesiology, Englewood Hospital and Medical Center, Englewood, NJ, USA
,
Charles Argoff2 Department of Neurology, Albany Medical Center, Albany, NY, USA
,
Jeffrey Fudin3 Professional Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9929-1909
ORCID Icon,
Emileigh Greuber4 Scilex Pharmaceuticals Inc., Palo Alto, CA, USAORCID Iconhttps://orcid.org/0000-0001-6450-1988
ORCID Icon,
Kip Vought4 Scilex Pharmaceuticals Inc., Palo Alto, CA, USA
,
Kalpana Patel4 Scilex Pharmaceuticals Inc., Palo Alto, CA, USA
&
Sri Nalamachu5 Mid America PolyClinic, Overland Park, KS, USA
 show all
Pages 1485-1496 | Published online: 22 Jun 2020

References

  • Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014;7:125–132. doi:10.2147/JPR.S57242
  • Shah S, Singaraju S, Einstein A, Sharma A. Herpes zoster: clinicocytopathological insight. J Oral Maxillofac Pathol. 2016;20(3):547. doi:10.4103/0973-029X.190968
  • Le P, Rothberg M. Herpes zoster infection. BMJ. 2019;364:kk5095. doi:10.1136/bmj.k5095
  • Hadley GR, Gayle JA, Ripoll J, et al. Post-herpetic neuralgia: a review. Curr Pain Headache Rep. 2016;20(3):17. doi:10.1007/s11916-016-0548-x
  • Jones J. Postherpetic neuralgia. J Pain Palliat Care Pharmacother. 2015;29(2):180–181. doi:10.3109/15360288.2015.1037520
  • Johnson RW, Rice AS, Solomon CG. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526–1533. doi:10.1056/NEJMcp1403062
  • Kondamudi PK, Tirumalasetty PP, Malayandi R, Mutalik S, Pillai R. Lidocaine transdermal patch: pharmacokinetic modeling and in vitro-in vivo correlation (IVIVC). AAPS PharmSciTech. 2016;17(3):588–596. doi:10.1208/s12249-015-0390-1
  • Stanos SP, Galluzzi KE. Topical therapies in the management of chronic pain. Postgrad Med. 2013;125(4 Suppl 1):25–33. doi:10.1080/00325481.2013.1110567111
  • ZTLIDO®. (Lidocaine Topical System): [Prescribing Information]. San Diego, CA, USA: Scilex Pharmaceuticals; 2018.
  • Cohen JI, Solomon CG. Herpes zoster. N Engl J Med. 2013;369(3):255–263. doi:10.1056/NEJMcp1302674
  • Gudin J, Nalamachu S. Utility of lidocaine as a topical analgesic and improvements in patch delivery systems. Postgrad Med. 2020;132(1):28–36. doi:10.1080/00325481.2019.1702296.
  • LIDODERM®. (Lidocaine Patch 5%): [Prescribing Information]. Malvern, PA, USA: Endo Pharmaceuticals; 2018.
  • Rowbotham MC, Davies PS, Verkermpinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65(1):39–44. doi:10.1016/0304-3959(95)00146-8
  • Galer B, Rowbotham M, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80(3):533–538. doi:10.1016/S0304-3959(98)00244-9
  • Hans G, Sabatwoski R, Binder A, Boesl I, Rogers P, Baron R. Efficacy and tolerability of 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin. 2009;25(5):1295–1305. doi:10.1185/03007990902901368
  • Sabatwoski R, Hans G, Tacken I, Kapanadze S, Buchheister B, Baron R. Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr Med Res Opin. 2012;28(8):1337–1346. doi:10.1185/03007995.2012.707977
  • Guidance for Industry. Assessing adhesion with transdermal and topical delivery systems for ANDAs. Rockville, MD, USA; 2018. Available from: https://www.fda.gov/media/98634/download. Accessed July 30, 2019.
  • Guidance for Industry. Assessing the irritation and sensitization potential of transdermal and topical delivery systems for ANDAs. Rockville, MD, USA; 2018. Available from: https://www.fda.gov/media/117569/download. Accessed July 30, 2019.
  • Guidance for Industry. Statistical approaches to establishing bioequivalence. Rockville, MD, USA; 2001. Available from: https://www.fda.gov/media/70958/download. Accessed July 30, 2019.
  • Wokovich AM, Prodduturi S, Doub WH, Hussain S, Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm. 2006;64(1):1–8. doi:10.1016/j.ejpb.2006.03.009

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.